{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:04:57Z","timestamp":1791983097095,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015984","name":"PerkinElmer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015984","id-type":"DOI","asserted-by":"crossref"}]},{"name":"College of American Pathologists"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Prenatal screening for common trisomies via cell-free (cfDNA) is usually implemented by technologies utilizing massively parallel sequencing, stringent environmental controls, complex bioinformatics, and molecular expertise. An alternative and less complex methodology utilizes rolling circle amplification (RCA). Further evaluation of its performance and related requirements are warranted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>At 16 sites, women at 10 to 20 weeks gestation provided informed consent, relevant information, and 2 to 3 blood samples. Samples shipped for testing were processed and stored. Women were enrolled at primary cfDNA screening, or following such screening at referral for diagnostic testing. RCA testing occurred post-enrollment, over 11 months. Diagnostic results and delivery notes determined clinical truth. Detection rates were based on confirmed trisomic pregnancies; false-positive rates were based on unaffected pregnancies from the general population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Detection rate for the common trisomies was 95.9% (117\/122, 95% CI, 90.5%\u201398.5%); overall false-positive rate was 1.00% (22\/2,205, 0.65%\u20131.51%). Test failure rate after repeat testing was 0.04%. When assay standard deviations were below pre-specified levels, the overall false-positive rate was much lower at 0.30% (P &amp;lt; 0.001). Fetal sex calls were correct for 99.7%. One technician analyzed 560 samples over 2 weeks, a rate of 14 000\/year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our assessment of this simplified cfDNA-based system for prenatal screening for common trisomies performed in a prenatal screening laboratory is encouraging. Improved detection, low failure rates and rapid reporting can be achieved by collecting 2 samples. Future priorities should include achieving higher run precision using a single collection tube.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinicaltrials.gov Registration Number<\/jats:title>\n                  <jats:p>NCT03087357.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvac131","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T16:21:21Z","timestamp":1663172481000},"page":"1449-1458","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of a Simplified Cell-Free DNA Method for Prenatal Down Syndrome Screening"],"prefix":"10.1093","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-8449","authenticated-orcid":false,"given":"Glenn E","family":"Palomaki","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Women & Infants Hospital , Providence, RI , USA"},{"name":"Department of Pathology and Laboratory Medicine, Alpert Medical School at Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E","family":"Eklund","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Women & Infants Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M","family":"Kloza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Women & Infants Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geralyn M","family":"Lambert-Messerlian","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Women & Infants Hospital , Providence, RI , USA"},{"name":"Department of Pathology and Laboratory Medicine, Alpert Medical School at Brown University , Providence, RI , USA"},{"name":"Department of Obstetrics and Gynecology, Women & Infants Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"2022110223575289600_hvac131-B1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00006250-200701000-00054","article-title":"ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities","volume":"109","author":"ACOG Committee on Practice Bulletins","year":"2007","journal-title":"Obstet Gynecol"},{"key":"2022110223575289600_hvac131-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7110","article-title":"First and second trimester antenatal screening for Down\u2019s syndrome: the results of the serum, urine and ultrasound screening study (SURUSS)","volume":"7","author":"Wald","year":"2003","journal-title":"Health Technol Assess"},{"key":"2022110223575289600_hvac131-B3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/GIM.0b013e3182368a0e","article-title":"DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study","volume":"13","author":"Palomaki","year":"2011","journal-title":"Genet Med"},{"key":"2022110223575289600_hvac131-B4"},{"key":"2022110223575289600_hvac131-B5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/uog.17484","article-title":"Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis","volume":"50","author":"Gil","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022110223575289600_hvac131-B6","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1038\/s41598-018-22606-0","article-title":"Imaging single DNA molecules for high precision NIPT","volume":"8","author":"Dahl","year":"2018","journal-title":"Sci Rep"},{"key":"2022110223575289600_hvac131-B7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/pd.5528","article-title":"Clinical validation of a novel automated cell-free DNA screening assay for trisomies 21,13, and 18 in maternal plasma","volume":"39","author":"Ericsson","year":"2019","journal-title":"Prenat Diagn"},{"key":"2022110223575289600_hvac131-B8","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"2022110223575289600_hvac131-B9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/cimb43020068","article-title":"Assessment and clinical utility of a non-next-generation sequencing-based non-invasive prenatal testing technology","volume":"43","author":"Gormus","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"2022110223575289600_hvac131-B10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3390\/diagnostics11101837","article-title":"Clinical validation of fetal cfDNA analysis using rolling-circle-replication and imaging technology in Osaka (CRITO Study)","volume":"11","author":"Pooh","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2022110223575289600_hvac131-B11","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/pd.6050","article-title":"Cell-free DNA screening for fetal aneuploidy using the rolling circle method: a step towards noninvasive prenatal testing simplification","volume":"41","author":"Pavanello","year":"2021","journal-title":"Prenat Diagn"},{"key":"2022110223575289600_hvac131-B12","doi-asserted-by":"crossref","first-page":"e010002","DOI":"10.1136\/bmjopen-2015-010002","article-title":"Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis","volume":"6","author":"Taylor-Phillips","year":"2016","journal-title":"BMJ Open"},{"key":"2022110223575289600_hvac131-B13","first-page":"CD011767","article-title":"Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women","volume":"11","author":"Badeau","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2022110223575289600_hvac131-B14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/uog.14694","article-title":"A unified approach to risk assessment for fetal aneuploidies","volume":"45","author":"Wright","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022110223575289600_hvac131-B15","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1373\/clinchem.2018.288670","article-title":"Specifying a gold standard for the validation of fetal fraction estimation in prenatal screening","volume":"64","author":"Wald","year":"2018","journal-title":"Clin Chem"},{"key":"2022110223575289600_hvac131-B16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/clinchem\/hvab014","article-title":"Variability of \u201cReported Fetal Fraction\u201d in noninvasive prenatal screening (NIPS)","volume":"67","author":"Persson","year":"2021","journal-title":"Clin Chem"},{"key":"2022110223575289600_hvac131-B17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pd.6126","article-title":"Consequences of imprecision in fetal fraction estimation on performance of cell-free DNA screening for Down syndrome","volume":"42","author":"Persson","year":"2022","journal-title":"Prenat Diagn"},{"key":"2022110223575289600_hvac131-B18","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/gim.2018.22","article-title":"Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing","volume":"20","author":"Palomaki","year":"2018","journal-title":"Genet Med"},{"key":"2022110223575289600_hvac131-B19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/uog.21904","article-title":"Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate","volume":"56","author":"Hancock","year":"2020","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022110223575289600_hvac131-B20","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/pd.5918","article-title":"Not all low fetal fraction cell-free DNA screening failures are at increased risk for aneuploidy","volume":"41","author":"Caldwell","year":"2021","journal-title":"Prenat Diagn"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/68\/11\/1449\/46755275\/hvac131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/68\/11\/1449\/46755275\/hvac131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T23:59:08Z","timestamp":1667433548000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/68\/11\/1449\/6697955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,14]]},"published-print":{"date-parts":[[2022,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvac131","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,3]]},"published":{"date-parts":[[2022,9,14]]}}}